Multidrug resistance in cancer: role of ATP–dependent transporters
The DOI matches its Crossref record; 167 of the 168 references it cites were found in a registry or an index.
Abstract
Chemotherapeutics are the most effective treatment for metastatic tumours. However, the ability of cancer cells to become simultaneously resistant to different drugs--a trait known as multidrug resistance--remains a significant impediment to successful chemotherapy. Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents. Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A common mechanism of multidrug resistance consists in the overexpression of cancer drug–extruding ABC transporters in malignant cells (58).”
From SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition (2024) · cites this paper as [58]
In the citing paper
“Prior exposure to taxanes during treatment of mCRPC can induce resistance mechanisms, including upregulation of efflux pumps or mutations in tubulin, that may compromise the efficacy of microtubule inhibitor-based ADCs246,247.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [247]
Citations
Cites
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“But why can some patients be cured by these approaches and others respond transiently or incompletely? Host and tumour genetic alterations, epigenetic changes and tumour environment all seem to contribute to the complex story of cancer drug resistanc”
BackgroundOverexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322 · cited 1×
“cgi?l=9429">ABCG2 — also known as MXR (mitoxantrone-resistance gene), BCRP (breast cancer resistance protein) or ABC-P (ABC transporter in placenta”
BackgroundNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · cited 1×
“Recent studies have emphasized the importance of the tumour vasculature and an appropriate pressure gradient for adequate drug delivery to the tumou”
BackgroundBIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059 · cited 1×
“asp?DrugCode=A%2D10166&DrugName=PACLITAXEL%2CSEMI%2DSYNTHETIC+INTRAVEN%2E&DrugType=1">paclitaxel”
Self-citationChen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
Self-citationA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“The discovery of MRP1 stimulated a genomic search for homologues, leading to the discovery of eight additional members of the ABCC subfamily of transporters, of which six have been studied in some detai”
BackgroundThe Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M., Rzhetsky, A., & Allikmets, R. (2001) · Genome Research · doi:10.1101/gr.184901 · Cited by 1,748
Research works printed but not linked: 3
- Solary, E. et al. Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. Cancer 68, 1714–1719 (1991). · doi:10.1002/1097-0142(19911015)68:8<1714::aid-cncr2820680811>3.0.co;2-2
- Abraham, J. et al. A phase I study of the novel P-glycoprotein (PGP) antagonist, XR9576 in combination with vinorelbine. Proc. Am. Soc. Clin. Oncol. 20, 287 (2001).
- Fedeli, L. et al. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 64, 1805–1811 (1989). · doi:10.1002/1097-0142(19891101)64:9<1805::aid-cncr2820640908>3.0.co;2-d
Cited by
Items 801–900 of 1,041
Role of SLC7A11/xCT in Ovarian Cancer
Fantone, S., Piani, F., Olivieri, F., Rippo, M. R., Sirico, A., Simone, N. D., Marzioni, D., & Tossetta, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010587 · Cited by 110
Pakunlu, R. I., Cook, T. J., & Minko, T. (2003) · Pharmaceutical Research · doi:10.1023/a:1022687617318 · Cited by 109
Xiang, S., Dauchy, R. T., Hauch, A. T., Mao, L., Yuan, L., Wren, M. A., Belancio, V. P., Mondal, D., Frasch, T., Blask, D. E., et al. (2015) · Journal of Pineal Research · doi:10.1111/jpi.12239 · Cited by 109
“Expression of ABC transporters is a key event in the development of multidrug resistance in cancer cells [17].”
BackgroundPark, H., Park, W., & Na, K. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.05.063 · Cited by 103
Overview of Oroxylin A: A Promising Flavonoid Compound
Lu, L., Guo, Q., & Zhao, L. (2016) · Phytotherapy Research · doi:10.1002/ptr.5694 · Cited by 109
“…and members of the ATP binding cassette (ABC) transporter superfamily have well-established roles among which ABCB1 gene that encodes an efflux transporter P-glycoprotein (P-gp) or MDR1 is probably the most well known (Gottesman et al., 2002; Calcagno et al., 2007; Bram et al., 2009).”
BackgroundPienta, K. J., Hammarlund, E. U., Brown, J. S., Amend, S. R., & Axelrod, R. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020838118 · Cited by 105
Clinical trials and progress with paclitaxel in ovarian cancer
Kumar, S., Mahdi, Shah, Garg, Bryant, & Munkarah (2010) · International Journal of Women s Health · doi:10.2147/ijwh.s7012 · Cited by 103
“HER2/neu (c-erbB2) overexpression has also been implicated in paclitaxel resistance.(115,116) MDR phenotype, which can be mediated by several multidrug transporters, particularly the 170-kDa Pgp efflux pump encoded by the mdr1 gene, structurally altered α- and β-tubulins, and an impaired ability to polymerize tubulin…”
Fang, C., Kievit, F. M., Veiseh, O., Stephen, Z. R., Wang, T., Lee, D., Ellenbogen, R. G., & Zhang, M. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.06.028 · Cited by 100
“In drug-resistant cells like C6-ADR, intracellular free drug molecules can be removed from cytosol to extracellular space by ABC-mediated drug efflux [1].”
BackgroundEvolution of Resistance to Cancer Therapy
Michor, F., Nowak, M. A., & Iwasa, Y. (2005) · Current Pharmaceutical Design · doi:10.2174/138161206775201956 · Cited by 109
“This phenomenon is known as multidrug resistance [1, 2] and can result from changes that limit accumulation of drugs within cells by decreasing uptake, enhancing efflux, or affecting membrane lipids [3], block apoptosis which is activated by most anticancer drugs [4], induce general response mechanisms that detoxify d…”
The Xenobiotic Transporter Mdr1 Enforces T Cell Homeostasis in the Presence of Intestinal Bile Acids
Cao, W., Kayama, H., Chen, M. L., Delmas, A., Sun, A., Kim, S. Y., Rangarajan, E. S., McKevitt, K., Beck, A. P., Jackson, C. B., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.012 · Cited by 102
“MDR1 (ABCB1) is a membrane-associated, ATP-dependent efflux pump recognized for transporting chemotherapeutic drugs out of tumor cells (Gottesman et al., 2002).”
BackgroundFrank, M. H., Wilson, B. J., Gold, J. S., & Frank, N. Y. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.080 · Cited by 95
Current trends of targeted therapy for oral squamous cell carcinoma
Li, H., Zhang, Y., Xu, M., & Yang, D. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04028-8 · Cited by 112
“Multidrug resistance has always been a significant hurdle during cancer chemotherapy, so it is of great importance to prevent or reverse the effect of multidrug resistance in this process (Gottesman et al. 2002).”
BackgroundChen, H., Wang, Z., Zong, S., Chen, P., Zhu, D., Wu, L., & Cui, Y. (2015) · Nanoscale · doi:10.1039/c5nr03454j · Cited by 105
Structure and Function of ABCG2-Rich Extracellular Vesicles Mediating Multidrug Resistance
Goler-Baron, V., & Assaraf, Y. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016007 · Cited by 108
“These ATP-driven MDR efflux transporters differ markedly in substrate specificity, tissue distribution and intracellular localization [1,4,5,6].”
BackgroundMukherjee, B., Mukhopadhyay, R., Banerjee, B., Chowdhury, S., Mukherjee, S., Naskar, K., Allam, U. S., Chakravortty, D., Sundar, S., Dujardin, J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213839110 · Cited by 102
Terunuma, A., Jackson, K. L., Vogel, J. C., Kapoor, V., & Telford, W. G. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12531.x · Cited by 113
Strategies of polymeric nanoparticles for enhanced internalization in cancer therapy
Sun, L., Wu, Q., Peng, F., Liu, L., & Gong, C. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.07.013 · Cited by 105
Nanoways to overcome docetaxel resistance in prostate cancer
Ganju, A., Yallapu, M. M., Khan, S., Behrman, S. W., Chauhan, S. C., & Jaggi, M. (2014) · Drug Resistance Updates · doi:10.1016/j.drup.2014.04.001 · Cited by 109
“P-glycoprotein is a broad spectrum multidrug efflux pump which binds to the hydrophobic substrate through its transmembrane domain and ATP hydrolysis causes conformational change in the transporter leading to release of the drug to the outer leaflet or the extracellular space (Gottesman et al., 2002).”
BackgroundMDR Gene Expression Analysis of Six Drug-Resistant Ovarian Cancer Cell Lines
Januchowski, R., Wojtowicz, K., Sujka‐Kordowska, P., Andrzejewska, M., & Zabel, M. (2012) · BioMed Research International · doi:10.1155/2013/241763 · Cited by 107
Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action
Durán, I., Lambea, J., Maroto, P., González-Larriba, J. L., Flores, L. E., Granados-Principal, S. M., Graupera, M., Sáez, B., Vivancos, A. P., & Casanovas, O. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0463-4 · Cited by 105
Peptide Drug Conjugates and Their Role in Cancer Therapy
Heh, E., Allen, J. C., Ramirez, F., Lovasz, D., Fernandez, L., Hogg, T., Riva, H. R., Holland, N. A., & Chacon, J. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010829 · Cited by 107
“Doxorubicin works as a topoisomerase II inhibitor; however, its physiochemical properties make it incredibly challenging to increase intracellular doxorubicin to therapeutic levels [44].”
BackgroundPerez, E. A. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0005-6 · Cited by 114
“MRP1 also confers resistance to anthracyclines, antifolates, and vinca alkaloids; but not to taxanes, mitoxantrone, or cisplatin (Table 2) [17, 18, 23, 24].”
BackgroundNazli, C., Demirer, G. S., Yar, Y., Acar, H. Y., & Kızılel, S. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.07.049 · Cited by 112
Dendrimer-mediated approaches for the treatment of brain tumor
Dwivedi, N., Shah, J., Mishra, V. K., Amin, M. C. I. M., Iyer, A. K., Tekade, R. K., & Kesharwani, P. (2016) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2015.1133155 · Cited by 103
“[82] So strictly speaking, passive targeting approach and EPR effect are only capable for drug delivery to highly permeable solid tumors.”
BackgroundChemical approaches to targeting drug resistance in cancer stem cells
Sotiropoulou, P. A., Christodoulou, M. S., Silvani, A., Herold-Mende, C., & Passarella, D. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.05.002 · Cited by 100
Füredi, A., Szebényi, K., Tóth, S., Cserepes, M., Hámori, L., Nagy, V., Karai, E., Vajdovich, P., Imre, T., Szabó, P., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.010 · Cited by 100
Buczek, M. E., Escudier, B. J., Bartnik, E., Szczylik, C. A., & Czarnecka, A. M. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.10.001 · Cited by 107
“There are studies that postulate that mechanisms involved in multi-drug resistance determining RCC resistance to chemotherapy might be also involved in decreased intake of TKIs (5) [20].”
BackgroundRole of the Drug Transporter ABCC3 in Breast Cancer Chemoresistance
Andugulapati, S. B., Udupa, N., Chamallamudi, M. R., Gupta, V., & Rangarajan, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155013 · Cited by 111
“Several members of the ABCC family have been implicated in drug resistance [5].”
BackgroundNanomedicines for advanced cancer treatments: Transitioning towards responsive systems
van Elk, M., Murphy, B. P., Eufrásio-da-Silva, T., O’Reilly, D. P., Vermonden, T., Hennink, W. E., Duffy, G. P., & Ruiz‐Hernández, E. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.10.013 · Cited by 104
“The quick ef fl ux of DOX from cancer cells by overactivation of ATP binding transporters such as P-glycoprotein (P-gp) illustrates this critical issue (Gottesman et al., 2002).”
MnO2-Based Nanoplatform Serves as Drug Vehicle and MRI Contrast Agent for Cancer Theranostics
Zhang, M., Xing, L., Ke, H., He, Y., Cui, P., Zhu, Y., Jiang, G., Qiao, J.-B., Lu, N., Chen, H., et al. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b15247 · Cited by 100
Wen, C., Fu, L., Huang, J., Dai, Y., Wang, B., Xu, G., Wu, L., & Zhou, H. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10180 · Cited by 115
“elevated expression of aBc transporters has been reported to be associated with drug resistance in vivo and in vitro (6,7).”
Bioengineering Strategies for Designing Targeted Cancer Therapies
Alexander-Bryant, A. A., Berg-Foels, W. S. V., & Wen, X. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-407173-5.00002-9 · Cited by 115
“P A A uthor M anuscript (Gottesman et al., 2002; Shi Kam et al., 2004).”
Wu, C., Shukla, S., Calcagno, A. M., Hall, M. D., Gottesman, M. M., & Ambudkar, S. V. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2005 · Cited by 100
“ABCG2, also known as the placenta-specific ABC transporter and as the breast cancer resistance protein (3, 4), is a ‘‘half transporter’’ that most likely functions as a homodimer or higher form oligomer (5, 6) and can efflux a variety of anticancer drugs, including mitoxantrone, doxorubicin, topotecan, and SN-38 (7–9).”
BackgroundSelf-citationLapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance
Kuang, Y.-H., Shen, T., Chen, X., Sodani, K., Hopper-Borge, E., Tiwari, A. K., Lee, J. W. K. K., Fu, L.-W., & Chen, Z.-S. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.08.021 · Cited by 99
“These transporter proteins originate from one of the largest protein families which is divided into seven subfamilies (A–G) based on sequence similarities, including ABCB1, also called Pglycoprotein (P-gp) [11], and multidrug resistance proteins (MRPs, ABCCs) [14] and ABCG2 [15,16].”
BackgroundPeer, D., Dekel, Y., Melikhov, D., & Margalit, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-4046 · Cited by 98
“The eight cell lines used in this study fall into three categories: (1) drug-sensitive: HT29 (human colon carcinoma), P388/WT (murine leukemia), and MCF-7 (human breast carcinoma); (2) inherently resistant (P-glycoprotein): C-26 (Colon carcinoma ref.”
MethodHu, T., To, K. K. W., Wang, L., Zhang, L., Lu, L., Shen, J., Chan, R. L. Y., Li, M., Yeung, J. H. K., & Cho, C. H. (2014) · Phytomedicine · doi:10.1016/j.phymed.2014.06.013 · Cited by 99
Kim, J. E., Singh, R. R., Cho‐Vega, J. H., Drakos, E., Davuluri, Y., Khokhar, F. A., Fayad, L., Medeiros, L. J., & Vega, F. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.98 · Cited by 99
“The multidrug resistance phenotype is often associated with increased expression of ATP-binding cassette (ABC) transporters that mediate energy-dependent transport of substrate drugs out of the cell against a concentration gradient”
BackgroundVerhalen, B., Ernst, S., Börsch, M., & Wilkens, S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.301192 · Cited by 106
Zhou, M., Li, L., Li, L., Lin, X., Wang, F., Li, Q., & Huang, Y. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.11.005 · Cited by 99
Shamim, M., Perveen, M., Nazir, S., Hussnain, M., Mehmood, R., Khan, M. I., & Javed Iqbal, M. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2021.115607 · Cited by 105
Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections
Sauna, Z. E., Shukla, S., & Ambudkar, S. V. (2005) · Molecular BioSystems · doi:10.1039/b504392a · Cited by 98
Ho, M., Hogge, D. E., & Ling, V. W. T. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2007.11.014 · Cited by 111
Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol
Xu, D., Lu, Q., & Hu, X. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.11.031 · Cited by 99
“Since the first P-gp inhibitor— verapamil was found in the year of 1981, numerous compounds with varying efficacies have been reported, some of which are now in clinical trials [7].”
BackgroundSlomiany, M. G., Dai, L., Bomar, P. A., Knackstedt, T., Kranc, D. A., Tolliver, L. B., Maria, B. L., & Toole, B. P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0143 · Cited by 99
A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers
Ganta, S., Deshpande, D., Korde, A., & Amiji, M. M. (2010) · Molecular Membrane Biology · doi:10.3109/09687688.2010.497971 · Cited by 109
“Among the ABC transporters, P-gp, the encoded product of the human multidrug resistance gene (ABCB1/MDR1) family is the most widely studied transporter (Gottesman et al. 2002).”
BackgroundLmrCD is a major multidrug resistance transporter in Lactococcus lactis
Lubelski, J., de Jong, A., van Merkerk, R., Agustiandari, H., Kuipers, O. P., Kok, J., & Driessen, A. J. M. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05267.x · Cited by 99
“Most of multidrug transporters described in eukaryotes including the well-characterized human P-glycoprotein (Pgp), MRP1 and ABCG2 fall in the latter family and are ATP driven (Litman et al., 2001; Ouellette et al., 2001; Paulsen et al., 2001; Gottesman et al., 2002; Lage, 2003; Schinkel and Jonker, 2003).”
BackgroundTirrò, E., Consoli, M. L., Massimino, M., Manzella, L., Frasca, F., Sciacca, L., Vicari, L., Stassi, G., Messina, L., Messina, A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3248 · Cited by 107
“Well-characterized mechanisms of chemotherapeutic resistance include alterations of the specific target for an antiblastic agent, defects in the transport of the drug or increases of its metabolic clearance (15, 30).”
BackgroundJorfi, S., Ansa-Addo, E. A., Kholia, S., Stratton, D., Valley, S., Lange, S., & Inal, J. M. (2015) · Scientific Reports · doi:10.1038/srep13006 · Cited by 106
Chisholm, R. H., Lorenzi, T., & Clairambault, J. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.06.009 · Cited by 111
“It is not its object to describe the molecular mechanisms of drug resistance in single cells, which have been investigated in detail in numerous articles [106, 107, 127] and books [184, 264].”
BackgroundCarbon Nanomaterials for Targeted Cancer Therapy Drugs: A Critical Review
Hosnedlová, B., Kepinská, M., Fernández, C., Peng, Q., Ruttkay-Nedecký, B., Milnerowicz, H., & Kizek, R. (2018) · The Chemical Record · doi:10.1002/tcr.201800038 · Cited by 98
Targeting Lysosomes in Cancer as Promising Strategy to Overcome Chemoresistance—A Mini Review
Geisslinger, F., Müller, M., Vollmar, A. M., & Bartel, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01156 · Cited by 93
What Makes Tumors Multidrug Resistant?
Borst, P., Jonkers, J., & Rottenberg, S. (2007) · Cell Cycle · doi:10.4161/cc.6.22.4936 · Cited by 106
“43-45 (6) The Brca1‐/‐, p53‐/‐ mouse mammary tumors have obvious advantages as an experimental system, but also drawbacks.”
BackgroundDesign, Synthesis, and Biological Evaluation of New-Generation Taxoids
Ojima, I., Chen, J., Sun, L., Borella, C. P., Wang, T., Miller, M. L., Lin, S., Geng, X., Kuznetsova, L., Qu, C., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800086e · Cited by 98
Robey, R. W., Zhan, Z., Piekarz, R. L., Kayastha, G. L., Fojo, T., & Bates, S. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1423 · Cited by 98
Self-citationDuvvuri, M. (2005) · Frontiers in bioscience · doi:10.2741/1634 · Cited by 107
“Each of these topics has been reviewed elsewhere (3-9).”
BackgroundGreenhalgh, K., Ramiro‐Garcia, J., Heinken, A., Ullmann, P., Bintener, T., Pacheco, M. P., Bagińska, J., Shah, P., Frachet, A., Halder, R., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.001 · Cited by 103
“Therefore, the targeting of ABC transporter expression may be a promising strategy to sensitize drug-resistant cancer cells (Gottesman et al., 2002).”
InfluentialCapsaicin and Piperine Can Overcome Multidrug Resistance in Cancer Cells to Doxorubicin
Li, H., Krstin, S., Wang, S., & Wink, M. (2018) · Molecules · doi:10.3390/molecules23030557 · Cited by 106
“The ability of cancer cells to become simultaneously resistant to different structurally unrelated drugs, a trait known as multidrug resistance, remains a major problem associated with the curative treatment of cancer patients [3].”
BackgroundCancer stem cells as a therapeutic target in bladder cancer
Aghaalikhani, N., Rashtchizadeh, N., Shadpour, P., Allameh, A., & Mahmoodi, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26916 · Cited by 104
Alamzadeh, Z., Beik, J., Mirrahimi, M., Shakeri‐Zadeh, A., Ebrahimi, F., Komeili, A., Ghalandari, B., Ghaznavi, H., Kamrava, S. K., & Moustakis, C. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105235 · Cited by 97
Enzyme-Instructed Self-Assembly for Cancer Therapy and Imaging
Kim, B. J., & Xu, B. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00025 · Cited by 98
Cellular rewiring in lethal prostate cancer: the architect of drug resistance
Carceles‐Cordon, M., Kelly, W. K., Gomella, L. G., Knudsen, K. E., Rodríguez-Bravo, V., & Domenech, J. M. D. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0298-8 · Cited by 101
Catalano, A., Rodilossi, S., Rippo, M. R., Caprari, P., & Procopio, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406696200 · Cited by 98
De Boo, S., Kopecka, J., Brusa, D., Gazzano, E., Matera, L., Ghigo, D., Bosia, A., & Riganti, C. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-108 · Cited by 93
“Moreover NO itself was found to modulate the activity of Pgp and MRP3 transporters, for which doxorubicin is a substrate [1]: indeed NO lowers the Vmax of doxorubicin efflux by nitrating the MRP3 transporter in human colon cancer HT29 cells [5, 9].”
InfluentialSun, H. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050180t · Cited by 95
Benlloch, M., Ortega, A., Ferrer, P., Segarra, R., Obrador, E., Asensi, M., Carretero, J., & Estrela, J. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m408531200 · Cited by 92
Gangloff, A., Hsueh, W., Kesner, A. L., Kiesewetter, D. O., Pio, B. S., Pegram, M. D., Beryt, M., Townsend, A., Czernin, J. G., Phelps, M. E., et al. (2005) · PubMed · Cited by 105
Inhibition of ABC Transporters Abolishes Antimony Resistance inLeishmaniaInfection
Basu, J. M., Mookerjee, A., Banerjee, R., Saha, M. C., Singh, S. K., Naskar, K., Tripathy, G., Sinha, P. K., Pandey, K., Sundar, S., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01196-07 · Cited by 96
“tance, especially in cancer (23), we measured the total intra-”
BackgroundIn vivo RNA Interference–Mediated Ablation of MDR1 P-Glycoprotein
Pichler, A., Zelcer, N., Prior, J. L., Kuil, A., & Piwnica-Worms, D. R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0038 · Cited by 97
“HEK293 cells were transiently transfected with the shRNAi constructs together with pMDR1-eGFP and screened by fluorescence-activated cell sorting analysis for reduced GFP-mediated fluorescence.”
BackgroundInfluentialLiu, T., Li, Z., Zhang, Q., Bernstein, K. D. A., Lozano‐Calderón, S. A., Choy, E., Hornicek, F. J., & Duan, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.13148 · Cited by 99
“One of the major causes of multi-drug resistance (MDR) is the overexpression of the membrane bound drug transporter protein P-glycoprotein (P-gp) [7, 8].”
BackgroundPositioning of aminopeptidase inhibitors in next generation cancer therapy
Hitzerd, S. M., Verbrugge, S. E., Ossenkoppele, G., Jansen, G., & Peters, G. J. (2014) · Amino Acids · doi:10.1007/s00726-013-1648-0 · Cited by 95
Reversing multidrug resistance by intracellular delivery of Pluronic® P85 unimers
Hong, W., Chen, D., Zhang, X., Zeng, J., Hu, H., Zhao, X., & Qiao, M. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.08.032 · Cited by 96
“The major reason for that is the complex mechanisms through which the drug resistance exhibited [9,10].”
BackgroundProblems of glioblastoma multiforme drug resistance
Stavrovskaya, A. A., Shushanov, S. S., & Rybalkina, E. Y. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916020036 · Cited by 91
Lessons Learned from Two Decades of Anticancer Drugs
Liu, Z., Delavan, B., Roberts, R., & Tong, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.005 · Cited by 94
“Often, tumors display multiple drug resistance (MDR), which is one of the major reasons for the ineffectiveness and toxicity of chemotherapeutic agents [122].”
BackgroundInfluentialDatta, S., Choudhury, D., Das, A. K., Mukherjee, D. D., Dasgupta, M., Bandopadhyay, S., & Chakrabarti, G. (2019) · APOPTOSIS · doi:10.1007/s10495-019-01526-y · Cited by 104
Khalifa, A. M., Elsheikh, M. A., Khalifa, A., & Elnaggar, Y. S. R. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.08.034 · Cited by 103
Liu, X., Tee, H.-W., & Go, M. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.10.006 · Cited by 95
Chemoembolization in the Management of Liver Tumors
Stuart, K. E. (2003) · The Oncologist · doi:10.1634/theoncologist.8-5-425 · Cited by 95
Venkatraman, G., Benesch, M. G. K., Tang, X., Dewald, J. W., McMullen, T. P. W., & Brindley, D. N. (2014) · The FASEB Journal · doi:10.1096/fj.14-262659 · Cited by 96
“Increased expressions of the MDRTs ABCB1 (55), ABCC1 (56), and ABCG2 (57), as well as several antioxidant genes, are implicated in resistance to cancer therapies (58).”
BackgroundNobiletin enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cancer cells
Ma, W., Feng, S., Yao, X., Yuan, Z., Liu, L., & Xie, Y. (2015) · Scientific Reports · doi:10.1038/srep18789 · Cited by 97
Beck, K., Hayashi, K., Nishiguchi, B., Saux, O. L., Hayashi, M., & Boyd, C. D. (2003) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540305100704 · Cited by 94
“…identified as drug resistance proteins, ABCC proteins are all expressed in normal tissues and, in addition to exogenously administered drugs, these ABCC proteins also transport many endogenous substrates (reviewed in Borst et al. 1999; Renes et al. 2000b; Kruh et al. 2001; Gottesman et al. 2002).”
BackgroundChen, J., He, Z.-M., Wang, F., Zhang, Z., Liu, X., Zhai, D., & Chen, W. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.12.038 · Cited by 104
Buondonno, I., Gazzano, E., Jean, S. R., Audrito, V., Kopecka, J., Fanelli, M., Salaroglio, I. C., Costamagna, C., Roato, I., Mungo, E., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0048 · Cited by 98
“Dox is a substrate of ATP-binding cassette (ABC) transporters, such as ABCB1/P-glycoprotein (Pgp) andABCC1/multidrug resistance related protein 1 (MRP1), which efflux the drug outside the tumor cell and limit its cytotoxicity (4).”
Lopes-Rodrigues, V., Di Luca, A., Mleczko, J., Meleady, P., Henry, M., Pesic, M., Cabrera, D., van Liempd, S., Lima, R. T., O’Connor, R., et al. (2017) · Scientific Reports · doi:10.1038/srep44541 · Cited by 88
Bharathiraja, P., Yadav, P., Sajid, A., Ambudkar, S. V., & Prasad, N. R. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101004 · Cited by 103
Insight in eukaryotic ABC transporter function by mutation analysis
Frelet‐Barrand, A., & Klein, M. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.01.024 · Cited by 106
“and there is considerable interest in the potential role of Pgp in rendering tumor cells resistant to chemotherapeutic drugs [32–36].”
BackgroundChen, K. G., Szakács, G., Annereau, J., Rouzaud, F., Liang, X., Valencia, J. C., Nagineni, C. N., Hooks, J. J., Hearing, V. J., & Gottesman, M. M. (2005) · Pigment Cell Research · doi:10.1111/j.1600-0749.2005.00214.x · Cited by 93
“Indeed, both MDR1 and MRP1 are expressed in many human cancers, including leukemias and some solid tumors (Borst and Elferink, 2002; Gottesman et al., 2002; Haimeur et al., 2004).”
BackgroundSelf-citationDrug-loaded gold plasmonic nanoparticles for treatment of multidrug resistance in cancer
Lee, S., Kim, H. J., Kim, S. Y., Kwon, M. K., Kim, S., Cho, A. E.-H., Yun, M., Shin, J., & Yoo, K. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.068 · Cited by 97
Zhao, X.-Q., Xie, J., Chen, X.-G., Sim, H. M., Zhang, X., Liang, Y.-J., Singh, S., Talele, T. T., Sun, Y.-L., Ambudkar, S. V., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.076299 · Cited by 97
Chen, T., Wang, C., Liu, Q., Meng, Q., Sun, H., Huo, X., Sun, P., Peng, J., Liu, Z., Yang, X., et al. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.987062 · Cited by 98
“Furthermore, P-gp is known to be overexpressed in many multidrug-resistant cancer cells and thus it plays an important role in the development of resistance to anti-cancer agents.(4) Breast cancer is a common cancer among women worldwide.”
BackgroundSherman‐Baust, C. A., Becker, K. G., Wood, W. H., Zhang, Y., & Morin, P. J. (2011) · Journal of Ovarian Research · doi:10.1186/1757-2215-4-21 · Cited by 94
“Doxorubicin and paclitaxel resistance can both arise through a multidrug resistance (MDR)-type mechanism, which generally results from overexpression of ATP Binding cassette (ABC) transporters [17], while cisplatin resistance is not believe to have a significant MDR component.”
BackgroundA New View of Pathway-Driven Drug Resistance in Tumor Proliferation
Nussinov, R., Tsai, C., & Jang, H. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.02.001 · Cited by 102
“Drug efflux [83,84], a fundamental drug resistance mechanism that works by preventing drug action on its target, can be promoted by several membrane transporter proteins.”
BackgroundYagüe, E., Higgins, C. F., & Raguz, S. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302269 · Cited by 94
Huang, S., Chen, M., Shen, Y., Shen, W., Guo, H., Gao, Q., & Zou, X. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.10.011 · Cited by 94
miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2
Xu, K., Liang, X., Shen, K., Cui, D., Zheng, Y., Xu, J., Fan, Z., Qiu, Y., Li, Q., Ni, L., et al. (2012) · Biochemical Journal · doi:10.1042/bj20120386 · Cited by 93
Zhao, S., Sun, S., Jiang, K., Wang, Y., Liu, Y., Wu, S., Li, Z., Shu, Q., & Lin, H. (2019) · Nano-Micro Letters · doi:10.1007/s40820-019-0263-3 · Cited by 94
Costea, T., Vlad, O., Miclea, L. C., Ganea, C., Szöllõsi, J., & Mocanu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020401 · Cited by 101
Drug–drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1)
Aszalós, A. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.07.021 · Cited by 93
Oncolytic Reovirus Effectively Targets Breast Cancer Stem Cells
Marcato, P., Dean, C. A., Giacomantonio, C. A., & Lee, P. W. K. (2009) · Molecular Therapy · doi:10.1038/mt.2009.58 · Cited by 93
Arsenic-Specific Stem Cell Selection During Malignant Transformation
Tokar, E. J., Qu, W., Liu, J., Liu, W., Webber, M. M., Phang, J. M., & Waalkes, M. P. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq093 · Cited by 102
Parrish, K. E., Cen, L., Murray, J., Calligaris, D., Kizilbash, S., Mittapalli, R. K., Carlson, B. L., Schroeder, M. A., Sludden, J., Boddy, A. V., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0553 · Cited by 91
“The ATP-binding cassette (ABC) transporters multi-drug resistance 1 (MDR1) and breast cancer resistance protein (BCRP1) are located in the luminal membrane of brain capillary endothelial cells and function within the BBB to limit drug accumulation in the brain (28-30).”
Background
Metadata
- Authors
- Gottesman, M. M., Fojo, T., & Bates, S. E.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Fojo, Tito
- Venue
- Nature Reviews Cancer
- Published
- 2002-01-01
- Volume
- 2
- Issue
- 1
- Pages
- 48-58
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2006434892
- Cited by
- 5,536
- References
- 168
- Citations by year
- 2026: 144 · 2025: 173 · 2024: 183 · 2023: 228 · 2022: 231 · 2021: 257 · 2020: 305 · 2019: 281 · 2018: 318 · 2017: 322 · 2016: 329 · 2015: 333 · 2014: 326 · 2013: 296 · 2012: 274
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Keywords
- multidrug resistance, drug efflux pumps, chemoresistance, cancer chemotherapy, drug resistance mechanisms, metastatic cancer
- MeSH terms
- Adenosine Triphosphate, Antineoplastic Agents, Breast Neoplasms, Female, Forecasting, Multigene Family, Humans, Leukemia, Neoplasm Proteins, Neoplasms, Organ Specificity, Permeability, Structure-Activity Relationship, Drug Design, Xenobiotics, Biomarkers, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 1, ATP-Binding Cassette, Sub-Family C Proteins, Multidrug Resistance-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.